enzastaurin
enzastaurin is a pharmaceutical drug with 35 clinical trials. Historical success rate of 91.2%.
Success Metrics
Based on 31 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
27
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
91.2%
31 of 34 finished
8.8%
3 ended early
0
trials recruiting
35
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.
First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer
Clinical Trials (35)
Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.
First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer
Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy
A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients
Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo
Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy
Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")
A Study for Patients With Non-Hodgkin's Lymphomas
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer
Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas
A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers
A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma
Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer
Enzastaurin in Combination of Capecitabine to Treat Breast Cancer
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 35